Details for Patent: 8,722,085

Which drugs does patent 8,722,085 protect, and when does it expire?

Patent 8,722,085 protects CONTRAVE and is included in one NDA.

This patent has nineteen patent family members in thirteen countries.

Summary for Patent: 8,722,085

Title:	Methods for administering weight loss medications
Abstract:	Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
Inventor(s):	McKinney; Anthony (San Diego, CA), Tollefson; Gary (Indianapolis, IN), Weber; Eckard (San Diego, CA), Soltero; Rick (Holly Springs, NC)
Assignee:	Orexigen Therapeutics, Inc. (La Jolla, CA)
Application Number:	12/838,364
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,722,085
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,722,085

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes						USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE

International Family Members for US Patent 8,722,085

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	063958
Australia	2007319472
Canada	2668885
Chile	2007003246